Related Experiment Videos
Gene therapy approaches in urologic oncology
1Division of Urologic Surgery, Duke University Medical Center, Durham, North Carolina, USA.
Surgical Oncology Clinics of North America
|April 1, 1995
Summary
Cytokine gene-based immunotherapy using tumor cells shows promise for urologic cancers. Preclinical studies demonstrate its ability to stimulate immune responses and provide therapeutic benefits, paving the way for clinical trials.
Area of Science:
- Oncology
- Immunotherapy
- Cancer Research
Background:
- Cytokine gene-based immunotherapy is an emerging field for treating urologic malignancies.
- Preclinical models of renal cell, bladder, and prostate carcinoma are used to evaluate novel treatment strategies.
Purpose of the Study:
- To assess the efficacy of cytokine-secreting, growth-inactivated tumor cell preparations in preclinical models.
- To explore the potential of gene-based immunotherapy for urologic cancers.
Main Methods:
- Utilizing cytokine-secreting, growth-inactivated tumor cell preparations in animal models.
- Evaluating the induction of T-cell responses against tumors.
- Assessing therapeutic benefits and immunologic memory establishment.
Main Results:
- Cytokine-secreting tumor cells induced T-cell responses even in non-immunogenic tumors.
- Significant therapeutic benefits were observed in tumor-bearing animals.
- Effective immunologic memory was established in cured animals.
Conclusions:
- Preclinical findings support the efficacy and therapeutic use of cytokine-secreting tumor cells.
- Results provide a rationale for clinical translation of this immunotherapy approach.
- Future research may involve genetically modified dendritic cells for enhanced immune stimulation.